ALK-Abelló A/S
OTC: AKABY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carsten Hellmann
- Employees
- 2,566
- Headquarters
- Horsholm, Denmark
- IPO year
- 2013
- Website
- https://www.alk.net
Loading AKABY…
Loading profile data…Frequently asked questions about AKABY
What does ALK-Abelló A/S (AKABY) do?
ALK-Abelló A/S operates as a global leader in allergy solutions, serving markets across Europe, North America, and internationally. The company provides a diverse range of allergy immunotherapy (AIT) products, offered as injections, sublingual drops, and tablets, specifically formulated to address common allergies like house dust mite, grass, tr...
Where does AKABY trade?
ALK-Abelló A/S (AKABY) trades on the Other OTC.
What sector is AKABY in?
ALK-Abelló A/S (AKABY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ALK-Abelló A/S?
Carsten Hellmann is the chief executive officer of ALK-Abelló A/S (AKABY).
Where is ALK-Abelló A/S headquartered?
ALK-Abelló A/S is headquartered in Denmark.
Does AKABY pay a dividend?
Yes — ALK-Abelló A/S (AKABY) paid a trailing twelve-month dividend of USD 0.45 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did AKABY go public?
ALK-Abelló A/S (AKABY) completed its initial public offering in 2013.
Is AKABY an ADR?
Yes — AKABY is an American Depositary Receipt; its underlying shares trade on a non-US exchange. ALK-Abelló A/S reporting and dividends follow the underlying issuer.